| 31st week of 2022 patent applcation highlights part 25 |
| Patent application number | Title | Published |
|---|
| 20220242834 | Organic Compound, Light-Emitting Device, Light-Emitting Apparatus, Electronic Device, and Lighting Device - An electron-transport layer material with a low refractive index is provided. An organic compound represented by General Formula (G1) is provided. In General Formula (G1), one to three of Q | 2022-08-04 |
| 20220242835 | ISOXAZOLINE COMPOUNDS AND USE THEREOF - Disclosed are an isoxazoline compound and an application thereof. The structure of the compound is as shown in general formula (I). The definitions of substituents in the formula are described in the description. The description also discloses use of the compound of general formula (I) as an insecticide, acaricide and animal parasite control agent. | 2022-08-04 |
| 20220242836 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(- 3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF - In one aspect, the invention relates to a crystalline form of the structure: | 2022-08-04 |
| 20220242837 | EFFICIENT NEW PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE - Described herein are novel methods of synthesizing 2-amino-5-chloro-N,3-dimethylbenzamide. Compounds prepared by the methods disclosed herein are useful for preparation of certain anthranilamide compounds that are of interest as insecticides, such as, for example, the insecticides chlorantraniliprole and cyantraniliprole. | 2022-08-04 |
| 20220242838 | PROCESS FOR THE PREPARATION OF FLUENSULFONE - This invention is directed to a method of oxidation of 5-chloro-2-((3,4,4-trifluorobut-3-en-1-yl)thio)-1λ | 2022-08-04 |
| 20220242839 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF CERTAIN NEMATICIDAL SULFONAMIDES - The present invention provides a method for preparing a compound of Formula C, Formula D, or Formula F: | 2022-08-04 |
| 20220242840 | PROCESS FOR SYNTHESIZING 5-HYDROXYMETHYLFURFURAL - The invention relates to a process for the production of a mixture of 5-hydroxymethylfurfural and glucose from a feedstock containing fructose in the presence of at least one polar aprotic solvent and of at least one dehydration catalyst, in which process the reaction temperature is less than 90° C. | 2022-08-04 |
| 20220242841 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA - Described herein is (3,5-dibromo-4-hydroxyphenyl)(6-hydroxy-2-(1-hydroxyethyl)benzofuran-3-yl-4,5,7-d | 2022-08-04 |
| 20220242842 | TANNIC ACID CURING AGENT AND PREPARATION METHOD AND APPLICATION THEREOF - A tannic acid curing agent and a preparation method thereof are provided. The present invention uses tannic acid as a raw material and the long fatty chain of 10-undecenoyl chloride is introduced into the tannic acid structure to obtain the tannic acid curing agent. The preparation method includes the following steps: mixing tannic acid, 10-undecenoyl chloride, a catalyst and a solvent for a substitution reaction to obtain undecylenyl tannic acid, in which the catalyst includes an acid binding agent and 4-diaminopyridine, and the solvent includes ethyl acetate and N, N-dimethylformamide; mixing the undecylenyl tannic acid, a mercapto compound, a solvent and a photoinitiator for an addition reaction under an ultraviolet irradiation to obtain the tannic acid curing agent, in which the mercapto compound is a mercapto carboxylic acid compound or a mercapto alcohol compound. | 2022-08-04 |
| 20220242843 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE - A process for preparing coumarin-caged forskolin derivatives, the forskolin derivatives themselves and to uses of the same. | 2022-08-04 |
| 20220242844 | CANNABINOID DERIVATIVES - The present disclosure relates to a cannabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a cannabinoid receptor in a subject in need thereof, such as acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, etc. The cannabinoid derivative has the following formula: | 2022-08-04 |
| 20220242845 | SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7 - The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines. | 2022-08-04 |
| 20220242846 | ISOINDOLINONE COMPOUNDS - Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I | 2022-08-04 |
| 20220242847 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS - The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC). | 2022-08-04 |
| 20220242848 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: | 2022-08-04 |
| 20220242849 | WDR5 INHIBITORS AND MODULATORS - Quinazolin-4(3H)-one, 2,3-dihydroquinazolin-4(1H)-one, 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, and 3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation. | 2022-08-04 |
| 20220242850 | PHTHALAZIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS - The present invention is directed to phthalazin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc. | 2022-08-04 |
| 20220242851 | CRYSTAL FORM AND SALT OF QUINAZOLINE COMPOUND AND PREPARATION METHOD THEREOF - The present invention relates to a crystal form and a salt of a compound serving as a Pan-HER tyrosine kinase inhibitor and a preparation method therefor, and also use thereof in the preparation of a medicament for treating solid tumors. | 2022-08-04 |
| 20220242852 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY - This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same. | 2022-08-04 |
| 20220242853 | MODIFIED CYANINE DYES AND CONJUGATES THEREOF - The present invention relates to the field of optical imaging More particularly, it relates to compounds of the cyanine family characterized by improved physico-chemical and biological properties and to their conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. | 2022-08-04 |
| 20220242854 | Small molecule inducers of autophagy - Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity. | 2022-08-04 |
| 20220242855 | Fused Imidazole Derivatives as IL-17 Modulators - A series of substituted fused bicyclic imidazole derivatives of formula (I), including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments including inflammatory and autoimmune disorders, wherein i. a. A represents C—R | 2022-08-04 |
| 20220242856 | CANNABINOID DERIVATIVES - This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in the treatment or prevention of a disease associated with a cannabinoid receptor, including receptors selected from CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor. | 2022-08-04 |
| 20220242857 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES - The present invention provides compounds of formula (I): | 2022-08-04 |
| 20220242858 | FXR (NR1H4) MODULATING COMPOUNDS - The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds. | 2022-08-04 |
| 20220242859 | INHIBITORS OF SARM1 - The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I). | 2022-08-04 |
| 20220242860 | POLYMORPH OF LATREPIRDINE DIHYDROCHLORIDE - The specification relates to a crystalline Latrepirdine dihydrochloride, Form DMB-I, method of its preparation, pharmaceutical composition containing it and its uses. | 2022-08-04 |
| 20220242861 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS - The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent cancer diseases and/or proliferative disorders using the compound. | 2022-08-04 |
| 20220242862 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 - The present invention relates to compounds which are inhibitors of CD38 and are useful in the treatment of cancer. | 2022-08-04 |
| 20220242863 | COMPOUNDS FOR TREATMENT OF EYE DISORDERS - Compounds of formula I as defined herein, or pharmaceutically acceptable salts, solvates or derivatives thereof, are potent inhibitors of angiogenesis and accordingly are of use in the treatment and prevention of various angiogenesis-related disorders such as cancer. | 2022-08-04 |
| 20220242864 | SUPERCRITICAL FLUID EXTRACTION PROCESS WITH INTEGRATED PRESSURE EXCHANGER - Processes and apparatuses for soluble compound recovery using supercritical fluid (SCF) are disclosed. An example process involves solvent extraction of a soluble compound using a SCF from a solid or liquid substrate including, but not limited to, microalgae, plant matter, and polymers. The apparatus comprises SCF, an extraction vessel, a pressure exchanger, a separate soluble compound, and solid or liquid compound separators. | 2022-08-04 |
| 20220242865 | INHIBITORS OF CYCLIN-DEPENDENT KINASES - The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. | 2022-08-04 |
| 20220242866 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE - The present invention provides processes for the preparation of 2-fluoroadenine, as well as certain intermediates useful in the preparation of 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine (EFdA): EFdA. | 2022-08-04 |
| 20220242867 | NOVEL IMIDAZOPYRIMIDINE COMPOUNDS AND USES THEREOF - The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. | 2022-08-04 |
| 20220242868 | CO-CRYSTALS OF A BRUTON'S TYROSINE KINASE INHIBITOR - Disclosed are co-crystals of the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the co-crystals, as well as methods of using co-crystals, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2022-08-04 |
| 20220242869 | CONDENSED HETEROCYCLIC COMPOUND HAVING A BRIDGEHEAD NITROGEN ATOM OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE - Objects of the present invention are to develop and provide a compound or a salt thereof, and a novel agricultural or horticultural insecticide containing the compound or the salt thereof, and to provide an agent for eliminating ectoparasites or endoparasites of animals. The objects can be achieved by a compound in which a pyridine ring containing an oxime group is bound to a condensed heterocyclic compound having a bridgehead nitrogen atom represented by the following general formula (1): | 2022-08-04 |
| 20220242870 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF - The present invention relates to a heterocycle-fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and HPK1, comprising the same as an active ingredient, and a method for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and using the same. | 2022-08-04 |
| 20220242871 | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF - The present disclosure relates to 5H-Pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds, and/or antibody conjugates thereof; and pharmaceutical compositions thereof, methods of producing the conjugates, and methods of using the conjugates and compositions for therapy. | 2022-08-04 |
| 20220242872 | E3 LIGASE BINDERS AND USES THEREOF - Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein bind an E3 ubiquitin ligase (e.g., Cereblon) and induce degradation of a transcription factor (e.g., IKZF1, IKZF3). Also provided are pharmaceutical compositions comprising the compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers (e.g., carcinoma); leukemia, lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer, multiple myeloma, and acute myeloid leukemia (AML))). Further provided are methods of inducing the degradation of a transcription factor (e.g., IKZF1, IKZF3) by administering a compound or composition described herein to a subject and/or to a biological sample (e.g., cell or tissue). | 2022-08-04 |
| 20220242873 | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT - A method for synthesizing a compound 2-[(2R,5S)-5-[2-methylfuro[3,2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitr ile as a selective JAK1/TYK2 kinase inhibitor. The compound is prepared by taking 7-chloro-6-nitrofuro[3,2-b]pyridine as the starting material, and by nucleophilic substitution, palladium on carbon reduction and cyclization reactions. The present synthesis method has mild reaction conditions, high product yield and high purity, and is suitable for industrial production. A crystal form of the compound, crystal forms of the salts thereof and preparation methods thereof. The crystal form of the compound and the crystal forms of the salts thereof have good physical and chemical properties and are suitable for drug development. | 2022-08-04 |
| 20220242874 | CAMPTOTHECIN DERIVATIVES - A compound of Formula I or a pharmaceutically acceptable salt thereof (wherein X, Y, Z and n are defined herein). These compounds are useful in the treatment of diseases mediated by topoisomerase I enzyme such as cancers. Also provided are processes for the preparation of compounds of Formula I. The compounds are more water soluble, stable in buffer solution at various pH, and exhibit better anti-tumor activity and rapid release of SN-38 in tumor microenvironments. | 2022-08-04 |
| 20220242875 | INHIBITORS OF KRAS G12C - Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): | 2022-08-04 |
| 20220242876 | HETEROCYCLIC COMPOUNDS - The invention provides new heterocyclic compounds having the general formula (I) | 2022-08-04 |
| 20220242877 | BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF - A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase. | 2022-08-04 |
| 20220242878 | RAPAMYCIN DERIVATIVES - The disclosure relates to compounds of formula (I) | 2022-08-04 |
| 20220242879 | FUSED HETEROCYCLE DERIVATIVES - The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection. | 2022-08-04 |
| 20220242880 | PROCESS FOR PREPARATION OF MIDOSTAURIN - The present application relates to a process for the preparation of midostaurin by controlling critical impurities or by-products which in turn lead to increase in the overall yield and purity. The present application also provides midostaurin having less than 0.15% or substantially free or free of one or more impurities. | 2022-08-04 |
| 20220242881 | HETEROAROMATIC PHOTOACTIVE COMPOUNDS FOR TRANSPARENT PHOTOVOLTAIC DEVICES - Photoactive compounds are disclosed. The disclosed compounds can include a structural motif of A-D-A, A-pi-D-A, or A-pi-D-pi-A, with A being an electron acceptor moiety, pi being a π-bridging moiety, and D being an electron donor moiety comprising a fused heteroaromatic group. The disclosed photoactive compounds can be used in organic photovoltaic devices, such as visibly transparent or opaque photovoltaic devices. | 2022-08-04 |
| 20220242882 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS - Disclosed are compounds that possess inhibitory activity against FAK. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat cancer mediated by aberrant FAK activity. | 2022-08-04 |
| 20220242883 | Antitumoral Compounds - A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same. | 2022-08-04 |
| 20220242884 | DNA-DEPENDENT PROTEIN KINASE INHIBITOR - Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat DNA-PK related disorder (e.g., cancer). | 2022-08-04 |
| 20220242885 | SYNTHESIS METHODS AND COMPOSITIONS OF LOW INTERMEDIATE AND LOW DICHELATE INTERMEDIATE CONTRAST AGENTS - Macrocyclic gadolinium-based contrast agents (GCA) are synthesized by pathways characterized by the formation of a sequence of metastable complexes before obtaining the final stable complex. Commercial macrocyclic GCAs contain unstable metastable complexes. These metastable species quickly release free Gd3+ ions upon delivery into the body. Aqueous or dry/solid GCA with near zero metastable species content and methods of synthesizing the same are disclosed. | 2022-08-04 |
| 20220242886 | CHEMICAL COMPOUNDS - The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described. | 2022-08-04 |
| 20220242887 | METHOD FOR PREPARING ORGANOCHLOROSILANES - Organochlorosilanes are produced by reacting, in a fluidized bed reactor, a chloromethane-containing reactant gas with a particulate contact mass containing silicon and a catalyst, wherein the organochlorosilanes have the general formula (CH | 2022-08-04 |
| 20220242888 | PROCESS FOR PREPARING ORGANOTIN COMPOUNDS - Provided is a facile process for preparing certain organotin compounds having alkyl and alkylamino substituents. The process provides organotin precursor compounds, for example tris(dimethylamido)isopropyl tin, in a highly pure form. As such, the products of the process are particularly useful in the deposition of high-purity tin oxide films in, for example, extreme ultraviolet light (EUV) lithography techniques used in microelectronic device manufacturing. | 2022-08-04 |
| 20220242889 | PROCESS FOR PREPARING ORGANOTIN COMPOUNDS - Provided is a facile methodology for preparing certain organotin compounds having alkyl and alkylamino or alkyl and alkoxy substituents. The process provides the organotin compounds in a highly pure form which are particularly useful as precursors in the deposition of high-purity tin oxide films in, for example, extreme ultraviolet light (EUV) lithography techniques used in the manufacture of certain microelectronic devices. | 2022-08-04 |
| 20220242890 | NOVEL ORGANOGERMANIUM COMPOUND - The present invention relates to a compound of general formula (I) (wherein R1, R2, and R3 are each independently a hydrogen atom or a lower alkyl and X is an alkali metal cation, ammonium cation, or quaternary ammonium cation). This compound is highly soluble in water, and solutions thereof need not be neutralized when administered to the living body. The compound is useful as a medicine, etc. | 2022-08-04 |
| 20220242891 | SPIRO-BISPHOSPHOROUS COMPOUND, AND PREPARATION AND APPLICATION THEREOF - Disclosed are a spiro-bisphosphorous compound, and a preparation and application thereof. The spiro-bisphosphorous compound is expressed in formula (I), (II) or (III). | 2022-08-04 |
| 20220242892 | 1,2-BIS(DIPHENYLPHOSPHINOALKYLAMIDO)-1,2-DISUBSTITUTED ETHANE, AND ITS SYNTHESIS AND APPLICATION - The present invention relates to the design and synthesis of a class of novel chiral phosphine ligand, 1,2-bis(diphenylphosphinoalkylamido)-1,2-disubstituted ethane, and use in asymmetric catalytic reactions, such as asymmetric catalytic synthesis of pyrazoline-5-one with a chiral quaternary carbon center, i.e., highly enantioselective synthesis of 3-methyl-4-benzyl-4-(2-butyl-2,3-butadienyl)pyrazoline-5-one by using 3-methyl-4-benzylpyrazoline-5-one and benzyl (2-butyl-2,3-butadienyl) carbonate with tris(dibenzylideneacetone)dipalladium-chloroform adduct and this novel ligand as catalysts. The ligand designed by this present invention has the following advantages: the structure is novel, the synthesis and enlarge are simple, the enantioselective control effect in the practical reaction is excellent, which has a broad application prospect in chiral catalysis. | 2022-08-04 |
| 20220242893 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF - The present invention relates to conjugate compounds and methods of making and using same. | 2022-08-04 |
| 20220242894 | Ruthenium (II) Complexes and Their Use as AntiCancer Agents - The present invention relates to a compound of the following formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, in particular in the treatment of cancer. The present invention also relates to a pharmaceutical composition comprising such a compound and to a method for the preparation of such a compound. | 2022-08-04 |
| 20220242895 | LIQUID PHASE SEPARATION OF 2G SUGARS BY ADSORPTION ON A FAU ZEOLITE HAVING A SI/AL ATOMIC RATIO GREATER THAN 1.5 - The invention relates to a process for the liquid-phase separation of glucose from a mixture of C5 and C6 sugars comprising at least xylose and glucose, by adsorption of glucose on a zeolitic adsorbent based on FAU-type zeolite crystals having an Si/Al atomic ratio strictly greater than 1.5 comprising barium, wherein:
| 2022-08-04 |
| 20220242896 | METHODS AND KITS TO IMPROVE THE FLUORESCENT SIGNAL OF DMB-LABELED SIALIC ACIDS - The present invention provides methods and kits to improve the signal from sialic acids labeled with the dye 1, 2-diamino-4, 5-methylenedioxybenzene (“DMB”). The methods include labeling the sialic acids with DMB in an aqueous solution comprising the amino acid glycine, with pH adjusted to 1.5-3.2 by an acid, such as phosphoric acid or hydrochloric acid, and a reductant. | 2022-08-04 |
| 20220242897 | CONTINUOUS PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN - The present document relates to a process for the preparation of the crystalline form II of sotagliflozin from compound of formula (A), said process being continuously performed and comprising at least the steps of: a) performing in a reaction chamber the reaction of said compound of formula (A) in solution in toluene or in xylene or in mixture thereof, and preferably in toluene, and at least sodium methoxide and methanol, at a temperature below the boiling point of methanol, to form sotagliflozin in mixture with sodium salts; b) conducting in a crystallization chamber the crystallization of sotagliflozin formed in step a), in a non-aqueous solvent medium including at least toluene, or xylene or mixture thereof, and free of sodium salts, at a temperature of crystallization of the form II of sotagliflozin; and c) isolating the crystalline form II of sotagliflozin. | 2022-08-04 |
| 20220242898 | SGLT2/DPP4 INHIBITOR AND APPLICATION THEREOF - Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved. | 2022-08-04 |
| 20220242899 | OLIGOSACCHARIDE-PROTEIN CONJUGATES - Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate. | 2022-08-04 |
| 20220242900 | SUBSTITUTED BIPHENYL OR PHENYLHETEROARYL-MANNOSIDES AS ANTAGONISTS OF FIMH - Disclosed herein are new O-biphenyl- and O-phenylheteroarylmannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment of diseases such as urinary tract infection. | 2022-08-04 |
| 20220242901 | NOVEL IRON COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions. | 2022-08-04 |
| 20220242902 | METHODS FOR ENHANCED REMOVAL OF IMPURITIES DURING PROTEIN A CHROMATOGRAPHY - Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography. | 2022-08-04 |
| 20220242903 | A METHOD FOR SEPARATING BIOMOLECULES - The present disclosure is directed to method ( | 2022-08-04 |
| 20220242904 | PEPTIDE FOR TREATING INFLAMMATION AND WOUNDS - The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response. In addition, the peptide can bind to the integrin beta 1 of intestinal epithelial cells and increase the cell adhesion and migration via phosphor-FAK signal and tight junction markers are increased via FAK-RhoA signal and thus promote intestine regeneration. | 2022-08-04 |
| 20220242905 | MODIFIED PEPTIDES AND THEIR USE - The invention relates to a compound of formula (A) wherein n is an integer from 1 to 6, and R | 2022-08-04 |
| 20220242906 | Peptides and Compounds that Bind to Elongation Initiation Factor 4E - A peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX | 2022-08-04 |
| 20220242907 | INHIBITORS OF IL-15 AND THEIR USE IN TREATING AUTOIMMUNE/INFLAMMATORY DISORDERS - The present disclosure is directed to peptoids and peptoid multimers that inhibit IL-15 and their use in treating autoimomune/inflammatory diseases. | 2022-08-04 |
| 20220242908 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND - Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound YA-156, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R. | 2022-08-04 |
| 20220242909 | NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR-TARGETING POLYPEPTIDE AND USE THEREOF - A neuronal nicotinic acetylcholine receptor-targeting polypeptide and the use thereof are disclosed. The polypeptide has an amino acid sequence of SEQ ID NO:1, and includes four cysteine residues, Cys | 2022-08-04 |
| 20220242910 | AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF - The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases. | 2022-08-04 |
| 20220242911 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEX - The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer. | 2022-08-04 |
| 20220242912 | THERAPEUTIC PEPTIDES - Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism. | 2022-08-04 |
| 20220242913 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME - The present invention relates to a novel intermediate used for physiologically active polypeptides and a method for preparing the same. The novel intermediate may be effectively used as an intermediate for the preparation of physiologically active polypeptide pharmaceuticals, and may be efficiently used for the preparation of high-quality pharmaceuticals by providing a polypeptide intermediate of high yield and high purity. | 2022-08-04 |
| 20220242914 | PEPTIDES AND USE THEREOF - The present invention relates to a cyclic peptide comprising an active region comprising the amino acid sequence X | 2022-08-04 |
| 20220242915 | SODIUM CHANNEL PROTEIN NAV1.4-TARGETING POLYPEPTIDE AND USE THEREOF - A sodium channel protein Nav1.4-targeting polypeptide is disclosed, which has an amino acid sequence of SEQ ID NO:1. The polypeptide includes a first disulfide bond between Cys-3 and Cys-17, a second disulfide bond between Cys-4 and Cys-23, and a third disulfide bond between Cys-12 and Cys-24. The polypeptide has a complex coiled structure consisting of a main chain and disulfide bonds, in which three key residues LYS | 2022-08-04 |
| 20220242916 | Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof - The present disclosure provides a synthetic peptide containing an amino acid sequence that can be used to produce antibodies against proteins derived from a new coronavirus (SARS-CoV-2). The synthetic peptide disclosed herein is recognized as an antigen relative to at least one mammal, contains an amino acid sequence which is LNESLIDLQELGKYEQYIKWP (SEQ ID No: 1), and has a total number of amino acid residues of 25 or less. | 2022-08-04 |
| 20220242917 | COMPOSITIONS AND METHODS FOR PRODUCING ADENO-ASSOCIATED VIRAL VECTORS - The present disclosure provides compositions and methods to make and use ribonucleic acid sequences encoding viral proteins (e.g., Rep and Cap proteins) derived from adeno-associated viruses. The RNA sequences can be delivered into a host cell for viral packaging. | 2022-08-04 |
| 20220242918 | ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF - The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences. | 2022-08-04 |
| 20220242919 | METHODS OF PRODUCING GLYCOSYLATED PROTEINS - Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof. | 2022-08-04 |
| 20220242920 | IMMUNOGENIC COMPOSITION - The present invention discloses modified | 2022-08-04 |
| 20220242921 | NOVEL PEPTIDE DERIVED FROM PEP27 PEPTIDE AND USES THEREOF - A peptide according to an embodiment of the present in which, in the amino acid sequence of SEQ ID NO: 1, (i) 2nd and 4th amino acids are each substituted with tryptophan (W); (ii) 2nd, 4th, 11st and 13rd amino acids are each substituted with tryptophan; and (iii) 2nd, 4th, 19th, 20th, 22nd, 23rd, 26th and 27th amino acids are each substituted with tryptophan. The peptide can be usefully applied as an active ingredient for antibiotics, cosmetic compositions, food additives, feed additives, biological pesticides and quasi-drugs. | 2022-08-04 |
| 20220242922 | Biological Nanopores for Biopolymer Sensing and Sequencing Based on FRAC Actinoporin - The invention relates generally to the field of nanopores and the use thereof in various applications, such as analysis of biopolymers and macromolecules, typically by making electrical measurements during translocation through a nanopores. Provided is a system comprising a funnel-shaped proteinaceous nanopore comprising an α-helical pore-forming toxin that is a member from the actinoporin protein family, more in particular Fragaceatoxin C (FraC), a mutant FraC, a FraC paralog, or a FraC homolog. | 2022-08-04 |
| 20220242923 | COLD-SHOCK PROTEIN SCAFFOLD FOR ENGINEERING NON-ANTIBODY BINDING PROTEINS - Disclosed herein are compositions and methods directed to non-antibody protein scaffolds derived from cold-shock proteins. | 2022-08-04 |
| 20220242924 | C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER - The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology. | 2022-08-04 |
| 20220242925 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-04 |
| 20220242926 | FGF21 FC FUSION PROTEIN, GLP-1 FC FUSION PROTEIN, AND COMBINATION THERAPEUTIC AGENT COMPRISING SAME AND USE THEREOF - An FGF21 Fc fusion protein, a GLP-1 Fc fusion protein, and a combination therapeutic agent. The combination therapeutic agent consists of a first pharmaceutical composition comprising an FGF21 Fc fusion protein and a second pharmaceutical composition comprising a GLP-1 Fc fusion protein. The fusion proteins or a combination thereof is used for preventing or curing cardiovascular diseases and/or metabolic diseases; the diseases comprise obesity, diabetes, hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, diabetic cardiomyopathy, coronary atherosclerotic cardiomyopathy, and other diseases related to insulin resistance. | 2022-08-04 |
| 20220242927 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF - In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems. | 2022-08-04 |
| 20220242928 | METHODS OF TREATING CANCER - Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions. | 2022-08-04 |
| 20220242929 | IMMUNE CELLS EXPRESSING MODIFIED CELL RECEPTORS AND METHODS OF MAKING - This disclosure relates to immune cells (such as T cells or NK cells) modified in their cell surface receptors to recognize one or more target antigens, in particular tumor-associated antigens. This disclosure also relates to a simple method for editing cell receptors, in particular cell surface receptors naturally expressed by immune cells such as T cells or NK cells, to create modified immune cells (e.g., cytotoxic cells) targeted against one or more target antigens, in particular tumor-associated antigens. Further, this disclosure relates to stem cells modified in one or more endogenous genes encoding one or more cell surface receptors and capable of differentiating into immune cells expressing modified cell surface receptors that recognize one or more target antigens. In addition, this disclosure relates to methods of making such modified stem cells. | 2022-08-04 |
| 20220242930 | IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES - Provided are immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided. | 2022-08-04 |
| 20220242931 | COMPOSITIONS AND METHODS OF ACETYLCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS - The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR. | 2022-08-04 |
| 20220242932 | ULINASTATIN POLYPEPTIDES FOR TREATING DISEASES - Provided are methods and compositions comprising ulinastatin polypeptides for treating diseases associated with elevated neutrophil elastase (NE), including NE-associated lung and skin diseases. | 2022-08-04 |
| 20220242933 | ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF - In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides. | 2022-08-04 |
